Premium
A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib
Author(s) -
Caldwell Kenneth J.,
De La Cuesta Esther,
Morin Cara,
Pappo Alberto,
Helmig Sara
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28330
Subject(s) - medicine , trk receptor , tropomyosin , fibrosarcoma , receptor tyrosine kinase , tropomyosin receptor kinase c , tyrosine kinase , cancer research , pathology , neurotrophin , receptor , platelet derived growth factor receptor , myosin , microbiology and biotechnology , biology , growth factor
Infantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection is commonly curative; however, resection is sometimes not possible requiring additional multimodal treatment. IFS commonly harbors a fusion in one of the neurotrophic receptor tyrosine kinase ( NTRK ) genes. Larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase (TRK), has been shown to be well tolerated and effective in children as young as 1‐month old. We report a case of IFS in a newborn treated with larotrectinib. The patient experienced a rapid clinical and radiographic response demonstrating the potential to treat newborns with larotrectinib.